Bhandari R, Morey S, Hamoodi A, et al. - Considering that the prison population represents a critical group to prioritize for diagnosis and treatment for achieving the elimination of hepatitis C (HCV), a universal offer of blood-borne virus testing (UOBBVT) program and a new treatment pathway was introduced to seven North East England (NEE) Prisons, researchers here investigated the proportion of individuals with active HCV initiating direct-acting antivirals (DAAs). In addition, they determined the outcomes following DAA treatment and assessed the re-infection rate following sustained virological response (SVR). From March 2016 onwards, they performed data collection on BBVT uptake, HCV positivity, HCV treatment outcomes, and reinfection. BBV testing was done in 8,538 individuals; HCV antibody positivity and HCV RNA positivity was detected in 612 (7.2%) and 374 (4.4%) patients, respectively. Ultimately, DAAs were initiated in 266 (71%) individuals. Findings suggest that the NEE prison population had increased diagnosis and treatment of HCV following the implementation of a UOBBVT program and new treatment pathway. However, there was a high HCV re-infection rate among those who achieved SVR emphasizing the necessity to improve harm reduction approaches.